Abstract
Inactivation of integrase (IN) and reverse transcriptase (RT) can revoke the replication of HIV virions, and non-infectious HIV particles are desirable virus-like particle (VLP) vaccine candidates. Here, we produced inactive HIV-1 particles fit for vaccine and virological purposes by introducing a mutation into the pol sequence. Proviral DNA (pNL4-3) was cut at two points in the pol region using the BalI restriction enzyme and then religated. HEK 293T cells were transfected with the resultant plasmid (pmzNL4-3) to produce mutated virions. To confirm a production of VLPs and evaluate their biological activity the p24 load and syncytium formation (MT2 cells) were analyzed. The assay indicated that mzNL4-3 virions were assembled and contained functional envelope glycoproteins (ENV). In addition, mzNL4-3 virions were able to infect neither the MT2 nor HEK 293T cells. Furthermore, the immunogenicity of VLPs was investigated in a mouse model. According to the data on vaccinated mice, the titer of ENV-specific antibodies rose rapidly after a boosting injection. Moreover, lymphoid cells extracted from these mice proliferated after exposure to the antigen. The mzNL4-3 virus particles possessed immunogenic antigens of HIV and can effectively trigger humoral and CD4 immune responses. Non-infectious mzNL4-3 virions may also be used in biomedical experiments for improving the biological safety conditions. Moreover, the mzNL4-3 seems to be a promising candidate for further HIV-1 vaccine investigations.
Article PDF
Similar content being viewed by others
References
Sakuragi J., Iwamoto A., Shioda T. 2002. Dissociation of genome dimerization from packaging functions and virion maturation of human immunodeficiency virus type 1.1. J. Virol. 76, 959–967.
Bukrinsky M. 2004. A hard way to the nucleus. Mol. Med. 10, 1–5.
Rajasuriar R., Gouillou M., Spelman T., Read T., Hoy J., Law M., Cameron P.U., Petoumenos K., Lewin S.R. 2011. Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV observational database. PLoS One. 6, e20713.
Parren P.W., Gauduin M.C., Koup R.A., Poignard P., Fisicaro P., Burton D.R., Sattentau Q.J. 1997. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol. Lett. 57, 105–112.
McMichael A.J., Rowland-Jones S.L. 2001. Cellular immune responses to HIV. Nature. 410, 980–987.
Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B. 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103–6110.
van Gils M.J., Edo-Matas D., Bowles E.J., Burger J.A., Stewart-Jones G.B., Schuitemaker H. 2011. Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum. J. Virol. 85, 6986–6995.
Pantophlet R., Burton D.R. 2006. GP120: Target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24, 739–769.
Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654–665.
McBurney S.P., Young K.R., Ross T.M. 2007. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology. 358, 334–346.
Lakhashe S.K., Velu V., Sciaranghella G., Siddappa N.B., Dipasquale J.M., Hemashettar G., Yoon J.K., Rasmussen R.A., Yang F., Lee S.J., Montefiori D.C., Novembre F.J., Villinger F., Amara R.R., Kahn M., Hu S.L., Li S., Li Z., Frankel F.R., Robert-Guroff M., Johnson W.E., Lieberman J., Ruprecht R.M. 2011. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: Efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine. 29, 5611–5622.
Ye L., Wen Z., Dong K., Wang X., Bu Z., Zhang H., Compans R.W., Yang C. 2011. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines. PLoS One. 6, e14813.
Sugimoto C., Watanabe S., Naruse T., Kajiwara E., Shiino T., Umano N., Ueda K., Sato H., Ohgimoto S., Hirsch V., Villinger F., Ansari A.A., Kimura A., Miyazawa M., Suzuki Y., Yamamoto N., Nagai Y., Mori K. 2010. Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV. PLoS One. 5, e11678.
Zabihollahi R., Sadat S., Vahabpour R., Salehi M., Azadmanesh K., Siadat S., Azizi Saraji A., Pouriavali M., Momen S., Aghasadeghi M. 2012. Introducing a frameshift mutation to the Pol sequence of HIV-1 provirus and evaluation of the immunogenic characteristics of the mutated virions (RINNL4-3). Mol. Biol. (Mosk). 46, 467–472.
Nakamura T., Masuda T., Goto T., Sano K., Nakai M., Harada S. 1997. Lack of infectivity of HIV-1 integrase zinc finger-like domain mutant with morphologically normal maturation. Biochem. Biophys. Res. Commun. 239, 715–722.
Rinke C.S., Boyer P.L., Sullivan M.D., Hughes S.H., Linial M.L. 2002. Mutation of the catalytic domain of the foamy virus reverse transcriptase leads to loss of processivity and infectivity. J. Virol. 76, 7560–7570.
Corbin A., Grigorov B., Roingeard P., Darlix J.L., Muriaux D. 2008. Revisiting HIV-1 assembly. Med. Sci. (Paris). 24, 49–55.
Vorkunova G., Lupandin S., Bukrinskaya A. 2011. HIV-1 assembly initiated by p17 matrix protein. Mol. Biol. (Moscow). 45, 811–815.
Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59, 284–291.
Rezaei A., Zabihollahi R., Salehi M., Moghim S., Tamizifar H., Yazdanpanahi N., Amini G. 2007. Designing a non-virulent HIV-1 strain: Potential implications for vaccine and experimental research. J. Res. Med. Sci. 12, 227–234.
Zabihollahi R., Namazi R., Aghasadeghi M.R., Esfahani A.F., Sadat S.M., Modarressi M.H. 2012. The in vitro anti-viral potential of Setarud (IMOD), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials. Indian J. Pharmacol. 44, 448–453.
Zabihollahi R., Sadat S.M., Vahabpour R., Aghasadeghi M.R., Memarnejadian A., Ghazanfari T., Salehi M., Rezaei A., Azadmanesh K. 2011. Development of single-cycle replicable human immunodeficiency virus 1 mutants. Acta Virol. 55, 15–22.
Sadat S.M., Zabihollahi R., Vahabpour R., Azadmanesh K., Javadi F., Siadat S.D., Memarnejadian A., Parivar K., Khanahmad Shahreza H., Arabi Mianroodi R., Hekmat S., Aghasadeghi M.R. 2010. Designing and biological evaluation of single-cycle replicable HIV-1 system as a potential vaccine strategy. In: 20th European Congress of Clinical Microbiology and Infectious Diseases: Clinical Microbiology and Infection, Austria, p. S334.
Madani N., Hubicki A.M., Perdigoto A.L., Springer M., Sodroski J. 2007. Inhibition of human immunodeficiency virus envelope glycoprotein-mediated single cell lysis by low-molecular-weight antagonists of viral entry. J. Virol. 81, 532–538.
Zhu K., Dobard C., Chow S.A. 2004. Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J. Virol. 78, 5045–5055.
Diallo K., Marchand B., Wei X., Cellai L., Gotte M., Wainberg M.A. 2003. Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity. J. Virol. 77, 8621–8632.
Wei X., Liang C., Gotte M., Wainberg M.A. 2003. Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. Virology. 311, 202–212.
Hunter Z., Smyth H.D., Durfee P., Chackerian B. 2009. Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine. Vaccine. 28, 403–414.
Sadat S.M., Zabihollahi R., Aghasadeghi M.R., Vahabpour R., Siadat S.D., Memarnejadian A., Azadmanesh K., Parivar K. 2011. Application of SCR priming VLP boosting as a novel vaccination strategy against HIV-1. Curr. HIV Res. 9, 140–147.
Kent S.J., De Rose R., Mokhonov V.V., Mokhonova E.I., Fernandez C.S., Alcantara S., Rollman E., Mason R.D., Loh L., Peut V., Reece J.C., Wang X.J., Wilson K.M., Suhrbier A., Khromykh A. 2008. Evaluation of recombinant Kunjin replicon SIV vaccines for protective efficacy in macaques. Virology. 374, 528–534.
Hoxie J.A. 2010. Toward an antibody-based HIV-1 vaccine. Annu. Rev. Med. 61, 135–152.
Young K.R., McBurney S.P., Karkhanis L.U., Ross T.M. 2006. Virus-like particles: Designing an effective AIDS vaccine. Methods. 40, 98–117.
Kaufmann D.E., Bailey P.M., Sidney J., Wagner B., Norris P.J., Johnston M.N., Cosimi L.A., Addo M.M., Lichterfeld M., Altfeld M., Frahm N., Brander C., Sette A., Walker B.D., Rosenberg E.S. 2004. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J. Virol. 78, 4463–4477.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published in Russian in Molekulyarnaya Biologiya, 2013, Vol. 47, No. 2, pp. 258–266.
The article is published in the original.
Rights and permissions
About this article
Cite this article
Aghasadeghi, M.R., Zabihollahi, R., Sadat, S.M. et al. Production and evaluation of immunologic characteristics of mzNL4-3, a non-infectious HIV-1 clone with a large deletion in the pol-Sequence. Mol Biol 47, 228–235 (2013). https://doi.org/10.1134/S0026893313020027
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0026893313020027